TDMS Study 96001-05 Pathology Tables
NTP Experiment-Test: 96001-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 01/08/03 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:10:32 FINAL/RATS Facility: Battelle Northwest Chemical CAS #: 64742-88-7 Lock Date: 09/24/01 Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Include All a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 96001-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 01/08/03 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:10:32 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE CONTROL 550 1100 2200 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Moribund Sacrifice 12 19 15 23 Natural Death 2 1 3 2 Survivors Terminal Sacrifice 36 30 32 25 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Intestine Small, Jejunum (49) (49) (47) (48) Leiomyoma 1 (2%) Liver (49) (50) (50) (50) Salivary Glands (49) (50) (50) (50) Carcinoma 1 (2%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (49) (50) (50) (50) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (50) (50) (50) (50) Adenoma 1 (2%) Carcinoma 1 (2%) Adrenal Medulla (50) (50) (50) (50) Pheochromocytoma Malignant 1 (2%) Pheochromocytoma Complex 1 (2%) Pheochromocytoma Benign 2 (4%) 4 (8%) 2 (4%) 2 (4%) Islets, Pancreatic (49) (50) (50) (50) Adenoma 1 (2%) 1 (2%) Carcinoma 1 (2%) Pituitary Gland (49) (50) (50) (50) Pars Distalis, Adenoma 27 (55%) 34 (68%) 33 (66%) 28 (56%) Pars Distalis, Carcinoma 1 (2%) 1 (2%) Thyroid Gland (49) (50) (50) (50) C-Cell, Adenoma 3 (6%) 5 (10%) 2 (4%) 4 (8%) Page 2 NTP Experiment-Test: 96001-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 01/08/03 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:10:32 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE CONTROL 550 1100 2200 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM - cont C-Cell, Carcinoma 1 (2%) 2 (4%) 1 (2%) Follicular Cell, Adenoma 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Clitoral Gland (49) (50) (50) (50) Adenoma 3 (6%) 5 (10%) 6 (12%) Carcinoma 1 (2%) 2 (4%) 1 (2%) 1 (2%) Ovary (50) (50) (50) (50) Granulosa Cell Tumor Malignant 1 (2%) Uterus (49) (50) (50) (50) Leiomyosarcoma 1 (2%) Polyp Stromal 10 (20%) 9 (18%) 10 (20%) 9 (18%) Sarcoma Stromal 1 (2%) 1 (2%) Cervix, Sarcoma Stromal 1 (2%) Vagina (1) Sarcoma 1 (100%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (50) (50) (50) (50) Histiocytic Sarcoma 1 (2%) Lymph Node (5) (5) (5) (4) Lymph Node, Bronchial (12) (7) (8) (11) Lymph Node, Mandibular (3) (2) Lymph Node, Mesenteric (50) (50) (50) (49) Lymph Node, Mediastinal (45) (39) (42) (45) Carcinoma, Metastatic, Thyroid Gland 1 (2%) Spleen (49) (50) (50) (50) Sarcoma, Metastatic, Skin 1 (2%) Thymus (47) (47) (46) (48) Thymoma Malignant 1 (2%) ____________________________________________________________________________________________________________________________________ Page 3 NTP Experiment-Test: 96001-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 01/08/03 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:10:32 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE CONTROL 550 1100 2200 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (50) (50) (50) (50) Carcinoma 3 (6%) 2 (4%) 9 (18%) 7 (14%) Carcinoma, Multiple 1 (2%) 1 (2%) 1 (2%) Fibroadenoma 14 (28%) 13 (26%) 10 (20%) 16 (32%) Fibroadenoma, Multiple 5 (10%) 13 (26%) 12 (24%) 8 (16%) Fibroma 1 (2%) Skin (50) (50) (50) (50) Basal Cell Adenoma 1 (2%) Basal Cell Carcinoma 1 (2%) Keratoacanthoma 1 (2%) Sarcoma 1 (2%) Subcutaneous Tissue, Fibroma 2 (4%) Subcutaneous Tissue, Fibrosarcoma 2 (4%) Subcutaneous Tissue, Sarcoma 1 (2%) Subcutaneous Tissue, Schwannoma Benign 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM None ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (49) (50) (50) (50) Carcinoma, Metastatic, Pituitary Gland 1 (2%) Glioma Malignant 1 (2%) Cerebellum, Glioma Malignant 1 (2%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (49) (50) (50) (50) Alveolar/Bronchiolar Adenoma 1 (2%) Alveolar/Bronchiolar Carcinoma 1 (2%) Carcinoma, Metastatic, Mammary Gland 1 (2%) 2 (4%) 1 (2%) Pheochromocytoma Malignant, Metastatic, Adrenal Medulla 1 (2%) Pleura (48) (50) (50) (50) Mesothelium, Carcinoma, Metastatic, Lung 1 (2%) ____________________________________________________________________________________________________________________________________ Page 4 NTP Experiment-Test: 96001-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 01/08/03 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:10:32 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE CONTROL 550 1100 2200 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Zymbal's Gland (1) Carcinoma 1 (100%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (49) (50) (50) (50) Urinary Bladder (49) (50) (50) (50) Leiomyosarcoma 1 (2%) Transitional Epithelium, Papilloma 1 (2%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) *(50) Histiocytic Sarcoma 1 (2%) Leukemia Mononuclear 26 (52%) 28 (56%) 26 (52%) 29 (58%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 5 NTP Experiment-Test: 96001-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 01/08/03 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:10:32 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE CONTROL 550 1100 2200 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 44 50 50 48 Total Primary Neoplasms 102 118 127 123 Total Animals with Benign Neoplasms 37 47 42 43 Total Benign Neoplasms 65 81 79 78 Total Animals with Malignant Neoplasms 30 30 36 37 Total Malignant Neoplasms 37 37 48 45 Total Animals with Metastatic Neoplasms 2 1 4 2 Total Metastatic Neoplasm 2 1 4 2 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 6 NTP Experiment-Test: 96001-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 01/08/03 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:10:32 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE CONTROL 138 550 1100 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Moribund Sacrifice 18 27 21 27 Natural Death 3 4 8 7 Survivors Terminal Sacrifice 29 19 21 16 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Intestine Large, Cecum (49) (49) (48) (48) Intestine Small, Ileum (49) (48) (46) (46) Liver (50) (50) (50) (50) Cholangiocarcinoma 1 (2%) Hepatocellular Adenoma 1 (2%) 1 (2%) Mesentery (7) (11) (11) (13) Oral Mucosa (1) Squamous Cell Carcinoma 1 (100%) Stomach, Glandular (50) (50) (49) (50) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (50) (50) (50) Atrium, Carcinoma, Metastatic, Kidney 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Medulla (50) (50) (50) (50) Pheochromocytoma Malignant 1 (2%) 2 (4%) Pheochromocytoma Benign 5 (10%) 8 (16%) 12 (24%) 13 (26%) Bilateral, Pheochromocytoma Benign 1 (2%) 1 (2%) 4 (8%) Islets, Pancreatic (50) (50) (50) (50) Adenoma 3 (6%) 2 (4%) 1 (2%) 3 (6%) Carcinoma 1 (2%) 3 (6%) Pituitary Gland (50) (50) (50) (50) Pars Distalis, Adenoma 38 (76%) 36 (72%) 35 (70%) 31 (62%) Pars Distalis, Carcinoma 1 (2%) Page 7 NTP Experiment-Test: 96001-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 01/08/03 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:10:32 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE CONTROL 138 550 1100 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM - cont Thyroid Gland (50) (50) (50) (50) Bilateral, C-Cell, Adenoma 1 (2%) 1 (2%) C-Cell, Adenoma 7 (14%) 5 (10%) 5 (10%) 4 (8%) C-Cell, Carcinoma 2 (4%) 3 (6%) 2 (4%) Follicular Cell, Adenoma 1 (2%) Follicular Cell, Carcinoma 1 (2%) 1 (2%) 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM Peritoneum (14) (41) (41) (32) ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Epididymis (50) (50) (50) (50) Preputial Gland (50) (50) (50) (50) Adenoma 1 (2%) 2 (4%) 1 (2%) Carcinoma 1 (2%) 3 (6%) Prostate (50) (50) (50) (50) Carcinoma 1 (2%) Testes (50) (50) (50) (50) Bilateral, Interstitial Cell, Adenoma 26 (52%) 22 (44%) 28 (56%) 30 (60%) Interstitial Cell, Adenoma 15 (30%) 17 (34%) 10 (20%) 12 (24%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (50) (50) (50) (50) Lymph Node (7) (16) (11) (17) Lymph Node, Bronchial (15) (12) (16) (13) Carcinoma, Metastatic, Kidney 1 (6%) Lymph Node, Mesenteric (50) (50) (50) (50) Carcinoma, Metastatic, Thyroid Gland 1 (2%) Lymph Node, Mediastinal (42) (44) (43) (40) Carcinoma, Metastatic, Thyroid Gland 1 (3%) Spleen (50) (50) (50) (50) Thymus (49) (49) (47) (50) Thymoma Malignant 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ Page 8 NTP Experiment-Test: 96001-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 01/08/03 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:10:32 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE CONTROL 138 550 1100 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (50) (50) (50) (50) Carcinoma 1 (2%) 2 (4%) Fibroadenoma 3 (6%) 1 (2%) 2 (4%) 4 (8%) Skin (50) (50) (50) (50) Basal Cell Carcinoma 1 (2%) 1 (2%) 3 (6%) Squamous Cell Papilloma 1 (2%) 2 (4%) 2 (4%) Sebaceous Gland, Adenoma 3 (6%) 1 (2%) 1 (2%) Subcutaneous Tissue, Fibroma 2 (4%) 4 (8%) 2 (4%) 2 (4%) Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (2%) Subcutaneous Tissue, Hemangioma 1 (2%) Subcutaneous Tissue, Lipoma 2 (4%) 1 (2%) Subcutaneous Tissue, Schwannoma Benign 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (50) (50) (50) (50) Cranium, Osteosarcoma 1 (2%) Femur, Osteosarcoma 1 (2%) Skeletal Muscle (1) (1) (1) (1) Carcinoma, Metastatic, Thyroid Gland 1 (100%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (50) (50) (50) Astrocytoma Malignant 1 (2%) Carcinoma, Metastatic, Pituitary Gland 1 (2%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (50) (50) (50) (49) Alveolar/Bronchiolar Adenoma 1 (2%) 2 (4%) Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%) Carcinoma, Metastatic, Kidney 1 (2%) Osteosarcoma, Metastatic, Bone 1 (2%) Pheochromocytoma Malignant, Metastatic, Adrenal Medulla 1 (2%) Thymoma Malignant, Metastatic, Thymus 1 (2%) Nose (50) (50) (50) (50) Carcinoma, Metastatic, Oral Mucosa 1 (2%) Page 9 NTP Experiment-Test: 96001-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 01/08/03 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:10:32 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE CONTROL 138 550 1100 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM - cont Respiratory Epithelium, Adenoma 1 (2%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Zymbal's Gland (1) Carcinoma 1 (100%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (50) (50) (50) (50) Lipoma 1 (2%) Liposarcoma 1 (2%) Cortex, Renal Tubule, Adenoma 1 (2%) Pelvis, Transitional Epithelium, Carcinoma 1 (2%) Renal Tubule, Carcinoma 1 (2%) 1 (2%) Urinary Bladder (50) (50) (50) (50) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) *(50) Leukemia Mononuclear 25 (50%) 29 (58%) 30 (60%) 30 (60%) Lymphoma Malignant 1 (2%) Mesothelioma Malignant 1 (2%) 2 (4%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 10 NTP Experiment-Test: 96001-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 01/08/03 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:10:32 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE CONTROL 138 550 1100 MG/M3 MG/M3 MG/M3 ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 50 50 50 50 Total Primary Neoplasms 145 143 149 153 Total Animals with Benign Neoplasms 50 50 49 48 Total Benign Neoplasms 107 104 104 109 Total Animals with Malignant Neoplasms 33 33 35 35 Total Malignant Neoplasms 38 39 45 44 Total Animals with Metastatic Neoplasms 2 2 4 Total Metastatic Neoplasm 2 4 5 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 11 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------